Search by Drug Name or NDC
NDC 73475-3041-05 VYVGART 20 mg/mL Details
VYVGART 20 mg/mL
VYVGART is a INTRAVENOUS INJECTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by argenx US. The primary component is EFGARTIGIMOD ALFA.
MedlinePlus Drug Summary
Efgartigimod alfa-fcab injection is used to treat a certain form of myasthenia gravis (MG; a disorder of the nervous system that causes muscle weakness). Efgartigimod alfa-fcab is in a group of medications called monoclonal antibodies. It works by reducing a certain natural substance in the body that causes symptoms of myasthenia gravis.
Related Packages: 73475-3041-05Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Efgartigimod alfa-fcab Injection
Product Information
NDC | 73475-3041 |
---|---|
Product ID | 73475-3041_eda70bcd-00e6-4196-9826-00ef3cd2b26b |
Associated GPIs | 99398225302020 |
GCN Sequence Number | 082930 |
GCN Sequence Number Description | efgartigimod alfa-fcab VIAL 400MG/20ML INTRAVEN |
HIC3 | Z29 |
HIC3 Description | NEONATAL FC RECEPTOR (FCRN) INHIBITORS |
GCN | 51724 |
HICL Sequence Number | 047735 |
HICL Sequence Number Description | EFGARTIGIMOD ALFA-FCAB |
Brand/Generic | Brand |
Proprietary Name | VYVGART |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | EFGARTIGIMOD ALFA |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | INJECTION |
Route | INTRAVENOUS |
Active Ingredient Strength | 20 |
Active Ingredient Units | mg/mL |
Substance Name | EFGARTIGIMOD ALFA |
Labeler Name | argenx US |
Pharmaceutical Class | Neonatal Fc Receptor Blocker [EPC], Neonatal Fc Receptor Blockers [MoA] |
DEA Schedule | n/a |
Marketing Category | BLA |
Application Number | BLA761195 |
Listing Certified Through | 2024-12-31 |
Package
NDC 73475-3041-05 (73475304105)
NDC Package Code | 73475-3041-5 |
---|---|
Billing NDC | 73475304105 |
Package | 1 VIAL, SINGLE-DOSE in 1 CARTON (73475-3041-5) / 20 mL in 1 VIAL, SINGLE-DOSE |
Marketing Start Date | 2021-12-17 |
NDC Exclude Flag | N |
Pricing Information | N/A |